# A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

> **NCT00535236** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 341 (actual)

## Conditions studied

- Herpes Zoster
- Herpes Zoster-related Complications

## Interventions

- **BIOLOGICAL:** V212
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00535236
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-02
- **Primary completion:** 2010-01-25
- **Final completion:** 2010-01-26
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535236, "A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00535236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*